Biomarkers in systemic lupus erythematosus: challenges and prospects for the future
Open Access
- 18 July 2013
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 5 (4), 210-233
- https://doi.org/10.1177/1759720X13485503
Abstract
The search for lupus biomarkers to diagnose, monitor, stratify, and predict individual response to therapy is currently more intense than ever before. This effort is essential for several reasons. First, epidemic overdiagnosis and underdiagnosis of lupus, even by certified rheumatologists, leads to errors in therapy with concomitant side effects which may be more serious than the disease itself. Second, identification of lupus flares remains as much an art as it is a science. Third, the capacity to stratify patients so as to predict those who will develop specific patterns of organ involvement is not currently possible but would potentially lead to preventive therapeutic strategies. Fourth, only one new drug for the treatment of lupus has been approved by the US Food and Drug Administration in over 50 years. A major obstacle in this pipeline is the dearth of biomarkers available to prove a patient has responded to an experimental therapeutic intervention. This review will summarize the challenges faced in the discovery and validation of lupus biomarkers, the most promising lupus biomarkers identified to date, and the promise of future directions.Keywords
This publication has 144 references indexed in Scilit:
- B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levelsArthritis & Rheumatism, 2011
- Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activityArthritis & Rheumatism, 2010
- The Unexplained Female Predominance of Systemic Lupus Erythematosus: Clues from Genetic and Cytokine StudiesClinical Reviews in Allergy & Immunology, 2010
- Interferon‐regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation studyArthritis & Rheumatism, 2009
- Neutrophil gelatinase–associated lipocalin is a predictor of the course of global and renal childhood‐onset systemic lupus erythematosus disease activityArthritis & Rheumatism, 2009
- IL‐17‐producing γδ T cellsEuropean Journal of Immunology, 2009
- Origins and Mechanisms of miRNAs and siRNAsCell, 2009
- MicroRNA Control in the Immune System: Basic PrinciplesCell, 2009
- DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factorsClinical Immunology, 2008
- Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injuryPediatric Nephrology, 2006